vs
CareTrust REIT, Inc.（CTRE）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是CareTrust REIT, Inc.的1.6倍（$219.9M vs $134.9M），CareTrust REIT, Inc.净利率更高（82.5% vs -1.0%，领先83.5%），CareTrust REIT, Inc.同比增速更快（55.1% vs 2.0%），过去两年CareTrust REIT, Inc.的营收复合增速更高（46.2% vs 8.0%）
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CTRE vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$134.9M
营收增速更快
CTRE
高出53.1%
2.0%
净利率更高
CTRE
高出83.5%
-1.0%
两年增速更快
CTRE
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $134.9M | $219.9M |
| 净利润 | $111.3M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 82.5% | -1.0% |
| 营收同比 | 55.1% | 2.0% |
| 净利润同比 | 113.5% | 92.4% |
| 每股收益（稀释后） | $0.52 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTREOFIX
| Q4 25 | $134.9M | $219.9M | ||
| Q3 25 | $132.4M | $205.6M | ||
| Q2 25 | $112.5M | $203.1M | ||
| Q1 25 | $96.6M | $193.6M | ||
| Q4 24 | $86.9M | $215.7M | ||
| Q3 24 | $77.4M | $196.6M | ||
| Q2 24 | $68.9M | $198.6M | ||
| Q1 24 | $63.1M | $188.6M |
净利润CTREOFIX
| Q4 25 | $111.3M | $-2.2M | ||
| Q3 25 | $74.9M | $-22.8M | ||
| Q2 25 | $68.5M | $-14.1M | ||
| Q1 25 | $65.8M | $-53.1M | ||
| Q4 24 | $52.1M | $-29.1M | ||
| Q3 24 | $33.4M | $-27.4M | ||
| Q2 24 | $10.8M | $-33.4M | ||
| Q1 24 | $28.7M | $-36.0M |
毛利率CTREOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率CTREOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | 58.1% | -8.3% | ||
| Q2 25 | 61.3% | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | 43.0% | -9.6% | ||
| Q2 24 | 15.1% | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率CTREOFIX
| Q4 25 | 82.5% | -1.0% | ||
| Q3 25 | 56.6% | -11.1% | ||
| Q2 25 | 60.9% | -6.9% | ||
| Q1 25 | 68.1% | -27.4% | ||
| Q4 24 | 60.0% | -13.5% | ||
| Q3 24 | 43.2% | -13.9% | ||
| Q2 24 | 15.6% | -16.8% | ||
| Q1 24 | 45.6% | -19.1% |
每股收益（稀释后）CTREOFIX
| Q4 25 | $0.52 | $-0.05 | ||
| Q3 25 | $0.35 | $-0.57 | ||
| Q2 25 | $0.35 | $-0.36 | ||
| Q1 25 | $0.35 | $-1.35 | ||
| Q4 24 | $0.30 | $-0.76 | ||
| Q3 24 | $0.21 | $-0.71 | ||
| Q2 24 | $0.07 | $-0.88 | ||
| Q1 24 | $0.22 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.0M | $82.0M |
| 总债务越低越好 | $894.2M | — |
| 股东权益账面价值 | $4.0B | $450.0M |
| 总资产 | $5.1B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资CTREOFIX
| Q4 25 | $198.0M | $82.0M | ||
| Q3 25 | $712.5M | $62.9M | ||
| Q2 25 | $306.1M | $65.6M | ||
| Q1 25 | $26.5M | $58.0M | ||
| Q4 24 | $213.8M | $83.2M | ||
| Q3 24 | $377.1M | $30.1M | ||
| Q2 24 | $495.1M | $26.4M | ||
| Q1 24 | $451.2M | $27.0M |
总债务CTREOFIX
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | $157.2M | ||
| Q2 25 | $1.2B | $157.0M | ||
| Q1 25 | $822.1M | $156.9M | ||
| Q4 24 | $396.9M | $157.0M | ||
| Q3 24 | $396.7M | $118.5M | ||
| Q2 24 | $671.1M | $118.0M | ||
| Q1 24 | $595.9M | $118.2M |
股东权益CTREOFIX
| Q4 25 | $4.0B | $450.0M | ||
| Q3 25 | $4.0B | $442.5M | ||
| Q2 25 | $3.3B | $458.3M | ||
| Q1 25 | $2.9B | $458.3M | ||
| Q4 24 | $2.9B | $503.1M | ||
| Q3 24 | $2.4B | $525.9M | ||
| Q2 24 | $1.9B | $546.0M | ||
| Q1 24 | $1.7B | $570.3M |
总资产CTREOFIX
| Q4 25 | $5.1B | $850.6M | ||
| Q3 25 | $5.1B | $832.6M | ||
| Q2 25 | $4.7B | $837.2M | ||
| Q1 25 | $3.9B | $823.1M | ||
| Q4 24 | $3.4B | $893.3M | ||
| Q3 24 | $2.9B | $867.9M | ||
| Q2 24 | $2.7B | $882.0M | ||
| Q1 24 | $2.3B | $906.0M |
负债/权益比CTREOFIX
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | 0.36× | ||
| Q2 25 | 0.35× | 0.34× | ||
| Q1 25 | 0.28× | 0.34× | ||
| Q4 24 | 0.14× | 0.31× | ||
| Q3 24 | 0.16× | 0.23× | ||
| Q2 24 | 0.35× | 0.22× | ||
| Q1 24 | 0.36× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $394.0M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | 3.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CTREOFIX
| Q4 25 | $394.0M | $27.7M | ||
| Q3 25 | $100.9M | $12.4M | ||
| Q2 25 | $100.8M | $11.6M | ||
| Q1 25 | $71.4M | $-18.4M | ||
| Q4 24 | $244.3M | $23.7M | ||
| Q3 24 | $67.2M | $11.7M | ||
| Q2 24 | $53.0M | $9.0M | ||
| Q1 24 | $48.8M | $-18.6M |
自由现金流CTREOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K | ||
| Q1 24 | — | $-29.1M |
自由现金流率CTREOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% | ||
| Q1 24 | — | -15.4% |
资本支出强度CTREOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | 5.6% |
现金转化率CTREOFIX
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTRE
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
